financetom
Business
financetom
/
Business
/
Wireless tower operator SBA Communications beats Q3 revenue expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wireless tower operator SBA Communications beats Q3 revenue expectations
Nov 3, 2025 1:25 PM

Overview

* SBA Communications ( SBAC ) Q3 revenue beats analyst expectations

* Net income for Q3 declines compared to last year

* Company repurchased 958 thousand shares during and after Q3

Outlook

* Company updates 2025 site leasing revenue outlook to $2,568.0 mln-$2,578.0 mln

* Company revises target leverage range to 6.0x-7.0x net debt to LQA Adjusted EBITDA

* Company sees 2025 adjusted EBITDA between $1,909.0 mln and $1,919.0 mln

Result Drivers

* CARRIER INVESTMENT - Co attributes Q3 performance to significant network investments by carrier customers, expanding and densifying networks

* INTERNATIONAL LEASING - Co benefited from strong international leasing demand, inflation-linked escalators, and favorable foreign currency rates

* VERIZON AGREEMENT - Co signed a long-term master lease agreement with Verizon, expected to accelerate rollout of next-gen wireless services

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $732.32 $716.15

REVENUE mln mln (15

Analysts

)

Q3 EPS $2.20

Q3 Net $240.40

Income mln

Q3 $3.30

Adjusted

FFO Per

Share

Q3 $1.11

Dividend

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the specialized reits peer group is "buy"

* Wall Street's median 12-month price target for SBA Communications Corp ( SBAC ) is $237.50, about 19.4% above its October 31 closing price of $191.48

* The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biden And Harris' Push To Block $14.1B US Steel Acquisition By Nippon Steel Faces Committee Delay: Report
Biden And Harris' Push To Block $14.1B US Steel Acquisition By Nippon Steel Faces Committee Delay: Report
Sep 13, 2024
As President Joe Biden and Vice President Kamala Harris aim to block the $14.1 billion takeover of United States Steel Corporation ( X ) by Japanese Nippon Steel ( NISTF ) , the legislative committee responsible for reviewing the deal has delayed proposing recommendations to Biden’s desk. What Happened: Amid the mixed views over the deal by union members and...
BRIEF-Future Vision II Acquisition Announces Pricing Of $50,000,000 Initial Public Offering
BRIEF-Future Vision II Acquisition Announces Pricing Of $50,000,000 Initial Public Offering
Sep 13, 2024
Sept 11 (Reuters) - Future Vision II Acquisition Corp : * FUTURE VISION II ACQUISITION CORP. ANNOUNCES PRICING OF $50,000,000 INITIAL PUBLIC OFFERING Source text for Eikon: Further company coverage: ...
BRIEF-7-Eleven Owner Taps Nomura To Advise On Takeover Battle After Rejecting $39Bn Offer- FT
BRIEF-7-Eleven Owner Taps Nomura To Advise On Takeover Battle After Rejecting $39Bn Offer- FT
Sep 13, 2024
Sept 11 (Reuters) - * 7-ELEVEN OWNER TAPS NOMURA TO ADVISE ON TAKEOVER BATTLE AFTER REJECTING $39BN OFFER- FT Source text: https://tinyurl.com/2a5q7k6a Further company coverage: [3382.T ATD.TO 8604.T] ...
Bicara Therapeutics targets $265 mln proceeds in upsized US IPO
Bicara Therapeutics targets $265 mln proceeds in upsized US IPO
Sep 13, 2024
Sept 11 (Reuters) - Bicara Therapeutics, a TPG-backed biopharmaceutical company developing a therapy targeting tumors, said on Wednesday it plans to raise up to $265 million through an upsized initial public offering (IPO) in the United States. This marks an increase from the previous target of raising up to $212 million. Expectations of a forthcoming rate cut is motivating several...
Copyright 2023-2026 - www.financetom.com All Rights Reserved